Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (31-40 of 136) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|September 8, 2025
An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemiaMarkus Metzler, Susan Branford, Nobuko Hijiya, et al.
Blood Advances|February 7, 2019
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKINaranie Shanmuganathan, Susan Branford, Timothy P Hughes, et al.
Clinical Chemistry|July 22, 2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross, Dale B Watkins, Timothy P Hughes, et al.
Current Hematologic Malignancy Reports|April 25, 2026
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid LeukemiaZuhal Naderi, Teresa Sadras, Susan Branford, et al.
Bioinformatics (Oxford, England)|May 7, 2016
BAM-matcher: a tool for rapid NGS sample matchingPaul P S Wang, Wendy T Parker, Susan Branford, et al.
Leukemia Research|October 23, 2019
Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcriptKirsty Sharplin, Haley Altamura, Kerry Taylor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CMLSusan Branford, Adelina Fernandes, NurHezrin Shahrin, et al.
Blood|January 3, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileWendy T Parker, Musei Ho, Hamish S Scott, et al.
Pathology|July 14, 2015
A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection systemAnoop Enjeti, Neil Granter, Asma Ashraf, et al.
Oncotarget|March 24, 2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Verity A Saunders, Susan Branford, et al.
Pageof 14

Showing results (31-40 of 136) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|September 8, 2025
An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemiaMarkus Metzler, Susan Branford, Nobuko Hijiya, et al.
Blood Advances|February 7, 2019
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKINaranie Shanmuganathan, Susan Branford, Timothy P Hughes, et al.
Clinical Chemistry|July 22, 2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross, Dale B Watkins, Timothy P Hughes, et al.
Current Hematologic Malignancy Reports|April 25, 2026
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid LeukemiaZuhal Naderi, Teresa Sadras, Susan Branford, et al.
Bioinformatics (Oxford, England)|May 7, 2016
BAM-matcher: a tool for rapid NGS sample matchingPaul P S Wang, Wendy T Parker, Susan Branford, et al.
Leukemia Research|October 23, 2019
Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcriptKirsty Sharplin, Haley Altamura, Kerry Taylor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CMLSusan Branford, Adelina Fernandes, NurHezrin Shahrin, et al.
Blood|January 3, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileWendy T Parker, Musei Ho, Hamish S Scott, et al.
Pathology|July 14, 2015
A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection systemAnoop Enjeti, Neil Granter, Asma Ashraf, et al.
Oncotarget|March 24, 2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Verity A Saunders, Susan Branford, et al.
Pageof 14